Home > Medical Research Archives > Issue 149 > The heterogeneity and therapeutic resistance of glioblastoma
![](https://esmed.org/wp-content/uploads/2022/12/MRA-cover-150x150.png)
Published in the Medical Research Archives
Jun 2015 Issue
The heterogeneity and therapeutic resistance of glioblastoma
Published on Jun 22, 2015
DOI
Abstract
Over the past decades, there has been an increasing use of molecular biology and genetic approaches in the assessment and management of adult gliomas, overall improving our understanding of the disease biology and behavior. Despite of these advances, maximal therapeutic intervention, as well as numerous new drugs entering clinical trials, the prognosis of malignant gliomas remains dismal. In this review, we provide an overview of the recent advances in the classification system, major molecular aberrations relevant to the biology of malignant gliomas, and standard as well as experimental treatment strategies. In addition, we discuss the complexity of this deadly disease, emphasizing the challenges associated with the enormously high degree of heterogeneity including cellular hierarchies at the inter- and intra-patient level.
Author info
Author Area
Have an article to submit?
Submission Guidelines
Submit a manuscript
Become a member